Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of autoimmune diseases by oral tolerance to autoantigens.
Weiner HL, Miller A, Khoury SJ, Zhang ZJ, al-Sabbagh A, Brod SA, Lider O, Higgins P, Sobel R, Matsui M, et al. Weiner HL, et al. Among authors: higgins p. Adv Exp Med Biol. 1995;371B:1217-23. Adv Exp Med Biol. 1995. PMID: 7502787 Review. No abstract available.
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS; ECOSPOR III and ECOSPOR IV investigators. Kraft CS, et al. Infect Dis Ther. 2024 Oct;13(10):2209-2210. doi: 10.1007/s40121-024-01036-8. Infect Dis Ther. 2024. PMID: 39212853 Free PMC article. No abstract available.
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS; ECOSPOR III and ECOSPOR IV investigators. Kraft CS, et al. Infect Dis Ther. 2024 Oct;13(10):2105-2121. doi: 10.1007/s40121-024-01007-z. Epub 2024 Jun 28. Infect Dis Ther. 2024. PMID: 38941068 Free PMC article.
Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints.
Honap S, Jairath V, Sands BE, Dulai PS, Higgins PD, De Cruz P, Gutiérrez A, Kotze PG, Ye BD, Kobayashi T, Gearry RB, Olivera PA, Amiot A, Mosli MH, Al Awadhi S, Halfvarson J, Patel KV, Sebastian S, Danese S, Peyrin-Biroulet L. Honap S, et al. Among authors: higgins pd. Clin Gastroenterol Hepatol. 2024 Dec 14:S1542-3565(24)01082-6. doi: 10.1016/j.cgh.2024.10.029. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39681225 Free article.
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.
Ehlers JP, Hu A, Boyer D, Cousins SW, Waheed NK, Rosenfeld PJ, Brown D, Kaiser PK, Abbruscato A, Gao G, Heier J; ReCLAIM-2 (SPIAM-202) Study Investigators. Ehlers JP, et al. Ophthalmol Sci. 2024 Oct 9;5(1):100628. doi: 10.1016/j.xops.2024.100628. eCollection 2025 Jan-Feb. Ophthalmol Sci. 2024. PMID: 39605874 Free PMC article.
Gram-negative bloodstream infections in six German university hospitals, 2016-2020: clinical and microbiological features.
Mischnik A, Baltus H, Walker SV, Behnke M, Gladstone BP, Chakraborty T, Falgenhauer L, Gastmeier P, Gölz H, Göpel S, Häcker GA, Higgins PG, Imirzalioglu C, Käding N, Kramme E, Peter S, Rieg S, Rohde AM, Seifert H, Tacconelli E, Tobys D, Trauth J, Vehreschild MJGT, Xanthopoulou K, Rupp J, Kern WV; DZIF R-NET Study Group. Mischnik A, et al. Among authors: higgins pg. Infection. 2024 Nov 25. doi: 10.1007/s15010-024-02430-7. Online ahead of print. Infection. 2024. PMID: 39586959
Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniae.
Shein AMS, Wannigama DL, Hurst C, Monk PN, Amarasiri M, Wongsurawat T, Jenjaroenpun P, Phattharapornjaroen P, Ditcham WGF, Ounjai P, Saethang T, Chantaravisoot N, Badavath VN, Luk-In S, Nilgate S, Rirerm U, Srisakul S, Kueakulpattana N, Laowansiri M, Rad SMAH, Wacharapluesadee S, Rodpan A, Ngamwongsatit N, Thammahong A, Ishikawa H, Storer RJ, Leelahavanichkul A, Ragupathi NKD, Classen AY, Kanjanabuch T, Pletzer D, Miyanaga K, Cui L, Hamamoto H, Higgins PG, Kicic A, Chatsuwan T, Hongsing P, Abe S. Shein AMS, et al. Among authors: higgins pg. Sci Rep. 2024 Nov 22;14(1):28992. doi: 10.1038/s41598-024-79924-9. Sci Rep. 2024. PMID: 39578508 Free PMC article.
1,242 results